Evaluation of the coagulation and fibrinolytic systems in men with intermittent claudication

Angiology

Volumn 47, Issue 6, 1996, Pages 543-548

  Handa, Koichi ^a   Takao, Makiko ^a   Nomoto, Junko ^a   Oku, Keiko ^a   Shirai, Kazuyuki ^a   Saku, Keijiro ^a   Arakawa, Kikuo ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA 2 ANTIPLASMIN; ALPHA 2 MACROGLOBULIN; ANTITHROMBIN III; COMPLEMENT COMPONENT C1S INHIBITOR; FIBRINOGEN; LIPOPROTEIN; PLASMINOGEN; PROTEIN C; THROMBOMODULIN;

ADULT; AGED; ARTICLE; BINDING SITE; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM INJURY; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; HUMAN; INTERMITTENT CLAUDICATION; LIPOPROTEIN BLOOD LEVEL; MALE; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; RAYNAUD PHENOMENON; RISK FACTOR;

EID: 0029933048     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331979604700602     Document Type: Article

References (31)

1. Hughson WG, Mann JI, Garrod A: Intermittent claudication: Prevalence and risk factors. Br Med J 1:1379-1381, 1978.
2. Kannel WB, Skinner JJ, Schwartz MJ: Intermittent claudication: Incidence in Framingham study. Circulation 41:875-883, 1970.
3. Lithell H, Hedstrand H, Karlsson R: The smoking habits of men with intermittent claudication. Acta Med Scand 197:473-485, 1975.
4. Banerjee AK, Pearson J, Gilliland EL, et al: A six-year prospective study of fibrinogen and other risk factors associated with mortality in stable claudicants. Thromb Haemostasis 68:261-263, 1992.
5. Lowe GDO, Saniabadi A, Turner A, et al: Studies on haematocrit in peripheral arterial disease. Klin Wochenschr 64:969-974, 1986.
6. Johansson J, Egberg N, Johnsson H, et al: Serum lipoproteins and hemostatic function in intermittent claudication. Arterioscler Thromb 13:1441-1448, 1993.
7. Lowe GDO, Fowkes FGR, Dawes J, et al: Blood viscosity, fibrinogen, and activation of coagulation and leukocytes in peripheral arterial disease and the normal population in the Edinburgh Artery Study. Circulation 87:1915-1920, 1993.
8. Allian CC, Poon LS, Chan CSG, et al: Enzymatic determination of total serum cholesterol. Clin Chem 20:470-475, 1974.
9. Eggstein M, Krenz FH: Ein neue Bestimmung der Neutralfette im Blutserum und Besprechung der Methode. Klin Wochenschr 44:262-274, 1966.
10. Warnick GR, Albers JJ: A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol. J Lipid Res 19:65-76, 1978.
11. Abe A, Maeda S, Makino K, et al: Enzyme-linked immunosorbent assay of lipoprotein(a) in serum and cord blood. Clin Chim Acta 177:31-40, 1988.
12. Sokal RR, Rohlf FJ: Biometry. San Francisco: Freeman, 1969, pp 328-333.
13. Dick W, Cullmann W: Gegenwärtige diagnostische Moglichkeiten beim hereditaren Angioödem (HAE) und beim erworbenen Angioödem (AAE). Immun Infekt 13:113-118, 1985.
14. Scully MF, Kakkar W: Methods for semi micro or automated determination of thrombin, antithrombin, and heparin cofactor using the substrate, H-D-Phe-Pip-Arg-P-nitroanilide-2HCl. Clin Chim Acta 79:595-602, 1977.
15. Friberger P, Knos M, Gustavsson S, et al: Methods for determination of plasmin, antiplasmin and plasminogen by means of substrate S-2251. Haemostasis 7:138-145, 1978.
16. Mimuro J, Koike Y, Sumi Y, et al: Monoclonal anti- bodies to discrete regions in α2-plasmin inhibitor. Blood 69:446-453, 1987.
17. Pelzer H, Schwarz A, Heimburger N: Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemostasis 59:101-106, 1988.
18. Harpel PC: α2-Plasmin inhibitor α2-macroglobulin complex in plasma. J Clin Invest 68:46-55, 1981.
19. Takahashi H, Takakuwa E, Yoshino N, et al: Protein C levels in disseminated intravascular coagulation and thrombotic thrombocytopenic purpura: Its correlation with other coagulation parameters. Thromb Haemostasis 54:445-449, 1985.
20. Martinoli JL, Stocker K: Fast functional protein C assay using Protac, a novel protein C activator. Thromb Res 43:253-264, 1986.
21. Kodama S, Uchijima E, Nagai M, et al: One-step sandwich enzyme immunoassay for soluble human thrombomodulin using monoclonal antibodies. Clin Chim Acta 192:191-200, 1990.
22. The Guidelines Subcommittee of the WHO/ISH Mild Hypertension Liaison committee: 1993 guidelines for management of mild hypertension. Clin Exp Hypertens 15:1363-1395, 1993.
23. WHO Expert Committee on Diabetes Mellitus. WHO Technical Report Series 646. Geneva: WHO, 1980.
24. Loscalzo J, Weinfeld M, Fless GM, et al: Lipoprotein(a) fibrin binding and plasminogen activation. Arteriosclerosis 10:240-245, 1990.
25. Harpel PC, Gordon BR, Parker TS: Plasmin catalyzes binding of lipoprotein(a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci USA 86:3847-3851, 1989.
26. Alessi MC, Parra HJ, Joly P, et al: The increased plasma Lp(a): B lipoprotein particle concentration in angina pectoris is not associated with hypofibrinolysis. Clin Chimi Acta 188:119-127, 1990.
27. Widmann MD, Sumpio BE: Lipoprotein (a): A risk factor for peripheral vascular disease. Ann Vasc Surg 7:446-451, 1993.
28. Mölgaard J, Klausen IC, Lassvik C, et al: Significant association between low-molecular-weight apolipoprotein(a) isoforms and intermittent claudication. Arterioscler Thromb 12:895-901, 1992.
29. Dittman WA, Majerus PW: Structure and function of thrombomodulin: A natural anticoagulant. Blood 75:329-336, 1990.
30. Ishii H, Uchiyama M: Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemostasis 65:618-623, 1991.
31. Frisch EP: Decreased α2-antiplasmin levels in patients suffering from obstructive peripheral arterial disease. Thromb Res 19:701-703, 1980.